// App-Quantinova.ai

105 : Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).

Researchers

Presenter

  • Luis G. Paz-Ares

Principal Investigators

  • Alexander Luft

  • Ali Tafreshi

  • Mahmut Gumus

  • Julien Mazieres

  • Barbara Hermes

  • Filiz Cay Senler

  • Andrea Fulop

  • Jeronimo Rodriguez-Cid

  • Shunichi Sugawara

  • Ying Cheng

  • Silvia Novello

  • Balazs Halmos

  • Yue Shentu

  • Dariusz Kowalski

Medical Centers

  • University Hospital 12 de October, Madrid, Spain

  • Leningrad Regional Clinical Hospital, St. Petersburg, Russia

  • Austin Health, Waterways, Australia

  • Kartal Research and Training Hospital, Istanbul, Turkey

  • Hopital Larrey Centre Hospitalier Universitaire Toulouse, Toulouse, France

  • Universitts-Frauenklinik Tubingen, Tubingen, Germany

  • Ankara University Department of Medical Oncology, Ankara, Turkey

  • Orszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary, Budapest, Hungary

  • Oncology Center, Medica Sur Hospital, Mexico City, Mexico

  • Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan

  • Department of Oncology, Cancer Hospital of Jilin Province, Changchun, China

  • Department of Oncology, University of Turin, Orbassano (TO), Italy

  • Albert Einstein College of Medicine, Great Neck, NY

  • Merck & Co., Inc., Kenilworth, NJ

  • Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland

Locations

  • China

  • Japan

  • Italy

  • Poland

  • Spain

  • Turkey

  • Germany

  • Australia

  • United States

  • Mexico

  • France

  • Russia

  • Hungary

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

  • Tissue polypeptide-specific antigen

Drug/Treatment

  • Pembrolizumab

  • Carboplatin

  • Paclitaxel

  • taxane

Outcome

  • Unknown

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT02775435

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved